Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India

Antimicrob Agents Chemother. 2018 Jul 27;62(8):e02264-17. doi: 10.1128/AAC.02264-17. Print 2018 Aug.

Abstract

This prospective study shows that the rate of azole-resistant Aspergillus fumigatus (ARAF) in an immunocompromised Indian patient population with invasive aspergillosis (IA) is low, 6/706 (0.8%). This low rate supports the continued use of voriconazole as the first line of treatment. However, the ARAF isolates from India in this study exhibited three kinds of unreported cyp51A mutations, of which two were at hot spots, G54R and P216L, while one was at codon Y431C.

Keywords: India; antifungal susceptibility testing; azole-resistant Aspergillus fumigatus; cyp51A mutations; immunocompromised hosts; invasive aspergillosis; risk factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Aspergillus fumigatus / drug effects*
  • Aspergillus fumigatus / genetics
  • Aspergillus fumigatus / pathogenicity*
  • Azoles / pharmacology*
  • Child
  • Drug Resistance, Fungal / genetics
  • Female
  • Fungal Proteins / genetics
  • Humans
  • Immunocompromised Host
  • India
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Mutation / genetics
  • Prospective Studies
  • Voriconazole / pharmacology

Substances

  • Azoles
  • Fungal Proteins
  • Voriconazole